BPMC - Blueprint Medicines Corp Stock Price, Fair Value and News

88.96USD+2.11 (+2.43%)Delayed as of 22 Apr 2024, 12:55 pm ET

Market Summary

USD88.96+2.11

Delayedas of 22 Apr 2024, 12:55 pm

2.43%

BPMC Alerts

4 major insider sales recently.

BPMC Stock Price

View Fullscreen

BPMC RSI Chart

BPMC Valuation

Market Cap

5.3B

Price/Earnings (Trailing)

-10.49

Price/Sales (Trailing)

21.32

EV/EBITDA

-10.22

Price/Free Cashflow

-11.74

BPMC Price/Sales (Trailing)

BPMC Profitability

EBT Margin

-202.91%

Return on Equity

-388.17%

Return on Assets

-48.32%

Free Cashflow Yield

-8.52%

BPMC Fundamentals

BPMC Revenue

Revenue (TTM)

249.4M

Rev. Growth (Yr)

85.55%

Rev. Growth (Qtr)

27.21%

BPMC Earnings

Earnings (TTM)

-507.0M

Earnings Growth (Yr)

30.09%

Earnings Growth (Qtr)

17.05%

Breaking Down BPMC Revenue

52 Week Range

45.9789.53

(Low)(High)

Last 7 days

-0.3%

Last 30 days

-1.4%

Last 90 days

7.3%

Trailing 12 Months

80.6%

How does BPMC drawdown profile look like?

BPMC Financial Health

Current Ratio

3.76

BPMC Investor Care

Shares Dilution (1Y)

2.08%

Diluted EPS (TTM)

-8.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	204.6M	225.6M	216.2M	249.4M
2022	221.2M	230.5M	272.3M	204.0M
2021	640.3M	486.9M	333.5M	180.1M
2020	71.9M	312.5M	553.1M	793.7M
2019	50.0M	55.5M	61.0M	66.5M
2018	27.2M	33.0M	38.7M	44.5M
2017	26.8M	25.6M	27.5M	21.4M
2016	17.6M	22.0M	24.7M	27.8M
2015	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Blueprint Medicines Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	landsittel michael	acquired	180,250	36.05	5,000	chief financial officer
Mar 28, 2024	landsittel michael	sold	-475,000	95.00	-5,000	chief financial officer
Mar 20, 2024	albers jeffrey w.	sold	-2,188,260	87.2757	-25,073	-
Mar 20, 2024	albers jeffrey w.	acquired	178,287	7.1107	25,073	-
Mar 15, 2024	hurley ariel	acquired	12,008	15.01	800	principal accounting officer
Mar 15, 2024	landsittel michael	sold	-1,205,610	87.7826	-13,734	chief financial officer
Mar 15, 2024	landsittel michael	acquired	180,250	36.05	5,000	chief financial officer
Mar 15, 2024	hurley ariel	sold	-399,213	87.7583	-4,549	principal accounting officer
Mar 13, 2024	lee philina	acquired	22,974	13.1509	1,747	chief commercial officer
Mar 13, 2024	lee philina	sold	-725,277	90.3997	-8,023	chief commercial officer

Which funds bought or sold BPMC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	262	9,486	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	new	-	218,463	218,463	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 18, 2024	Diversified Trust Co	added	3.56	83,852	1,372,810	0.04%
Apr 16, 2024	CALTON & ASSOCIATES, INC.	sold off	-100	-223,518	-	-%
Apr 15, 2024	Pallas Capital Advisors LLC	added	0.62	16,652	496,023	0.02%
Apr 15, 2024	Ellsworth Advisors, LLC	new	-	422,552	422,552	0.12%
Apr 15, 2024	Security National Bank	sold off	-100	-2,859	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	18.59	56,110	311,615	0.01%
Apr 12, 2024	AdvisorNet Financial, Inc	new	-	1,423	1,423	-%

Are Funds Buying or Selling BPMC?

Are funds buying BPMC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BPMC

No. of Funds

BPMC Alerts

4 major insider sales recently.

Unveiling Blueprint Medicines Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	price t rowe associates inc /md/	10.2%	6,250,823	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	8.9%	5,435,617	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	7.03%	4,276,333	SC 13G/A
Jan 24, 2024	blackrock inc.	10.8%	6,584,176	SC 13G/A
Jan 10, 2024	vanguard group inc	10.06%	6,114,970	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	7.2%	4,299,290	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.65%	5,774,456	SC 13G/A

Recent SEC filings of Blueprint Medicines Corp

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 01, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Blueprint Medicines Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Blueprint Medicines Corp News

Latest updates

Blueprint Medicines Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	27.2%	71,957,000	56,566,000	57,570,000	63,287,000	38,781,000	65,977,000	36,547,000	62,731,000	107,021,000	24,188,000	27,295,000	30,700,500	34,106,000	745,118,000	375,642,500	6,167,000	51,533,000	9,139,000	5,110,000	3,071,500	1,033,000
Costs and Expenses	-4.6%	177,066,000	185,546,000	185,551,000	187,494,000	188,580,000	190,254,000	194,185,000	168,535,000	423,157,000	141,284,000	135,806,000	121,814,000	120,072,000	111,751,000	133,380,000	119,825,000	120,911,000	107,100,000	109,024,000	90,803,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120,911,000	107,100,000	109,024,000	90,803,000	84,175,000
S&GA Expenses	13.7%	80,417,000	70,741,000	71,931,000	70,950,000	64,020,000	57,608,000	58,688,000	57,058,000	54,199,500	49,806,000	49,286,000	42,002,000	42,539,500	37,375,000	42,174,000	35,655,000	32,265,000	25,647,000	21,923,000	16,553,000	13,643,000
R&D Expenses	-12.5%	96,434,000	110,252,000	110,063,000	112,073,000	117,839,500	127,981,000	128,466,000	103,133,000	356,876,500	84,419,000	80,027,000	79,710,000	77,404,500	74,230,000	91,079,000	84,146,000	88,646,000	81,453,000	87,101,000	74,250,000	70,532,000
EBITDA Margin	20.3%	-2.06	-2.58	-2.50	-2.86	-2.73	-2.61	-2.98	-2.89	-3.51	-1.20	0.72	0.53	0.41	-	-	-	-	-	-	-	-
Interest Expenses	-35.8%	-5,169,500	-3,808,000	-3,996,000	-5,819,000	-9,240,000	-8,396,000	427,000	442,000	463,000	552,000	633,000	738,000	936,000	1,173,000	1,586,000	2,904,000	2,989,500	3,758,000	4,275,000	2,710,000	10,505,000
Income Taxes	-63.5%	73,000	200,000	190,000	500,000	1,029,000	900,000	3,130,000	184,000	2,346,000	175,000	193,000	574,000	688,000	370,000	15,000	32,000	55,000	33,000	44,000	53,000	18,000
Earnings Before Taxes	17.0%	-110,856,000	-133,516,000	-132,603,000	-129,040,000	-157,610,000	-132,277,000	-156,579,000	-105,815,000	-316,053,000	-117,066,000	-108,251,000	-99,714,000	-84,980,000	634,348,000	-123,474,000	-	-	-94,275,000	-	-	-
EBT Margin	20.6%	-2.03	-2.56	-2.44	-2.81	-2.71	-2.61	-3.02	-2.93	-3.56	-1.23	0.70	0.51	0.40	-	-	-	-	-	-	-	-
Net Income	17.0%	-110,916,500	-133,713,000	-132,794,000	-129,560,000	-158,646,000	-133,163,000	-159,709,000	-105,999,000	-318,686,000	-117,241,000	-108,444,000	-99,714,000	-85,668,500	633,978,000	-123,474,000	-110,953,000	-66,331,000	-94,275,000	-99,681,000	-87,407,000	-80,322,000
Net Income Margin	20.8%	-2.03	-2.57	-2.46	-2.84	-2.73	-2.64	-3.04	-2.94	-3.58	-1.23	0.70	0.51	0.40	-	-	-	-	-	-	-	-
Free Cashflow	24.5%	-83,601,000	-110,734,000	-133,029,000	-125,545,000	-122,886,000	-133,619,000	-120,812,000	-133,879,000	-15,372,000	-96,592,000	-63,827,000	-125,951,000	-25,486,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.1%	1,049	1,105	1,106	1,220	1,350	1,458	1,192	1,143	1,252	1,477	1,569	1,625	1,718	1,558	817	914	708	738	807	545	594
Current Assets	0.0%	808	808	811	900	1,047	1,228	952	687	554	772	704	938	928	842	568	705	517	514	613	427	500
Cash Equivalents	27.4%	71.00	56.00	76.00	170	120	291	173	37.00	210	554	534	698	690	565	289	375	120	89.00	82.00	79.00	73.00
Inventory	29.0%	21.00	16.00	17.00	18.00	30.00	35.00	35.00	30.00	22.00	17.00	15.00	16.00	9.00	6.00	4.00	3.00	-	-	-	-	-
Net PPE	3.3%	42.00	41.00	37.00	34.00	33.00	33.00	33.00	31.00	31.00	31.00	32.00	33.00	34.00	35.00	37.00	38.00	38.00	38.00	34.00	31.00	30.00
Liabilities	1.8%	919	903	795	806	835	818	445	262	281	230	240	225	248	238	236	231	243	222	214	200	121
Current Liabilities	8.9%	215	197	169	173	183	176	159	137	150	120	125	112	131	110	105	98.00	106	94.00	82.00	65.00	60.00
LT Debt, Current	-	-	-	-	-	-	-	6.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	166	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-35.5%	131	203	311	414	515	640	748	882	971	1,247	1,329	1,400	1,470	1,320	581	683	464	516	593	344	419
Retained Earnings	-5.0%	-2,339	-2,229	-2,095	-1,962	-1,832	-1,674	-1,541	-1,381	-1,275	-956	-839	-731	-631	-545	-1,179	-1,056	-945	-878	-784	-684	-597
Additional Paid-In Capital	1.6%	2,474	2,434	2,411	2,381	2,358	2,329	2,303	2,275	2,250	2,209	2,174	2,136	2,107	1,868	1,762	1,739	1,412	1,395	1,376	1,029	1,017
Shares Outstanding	0.7%	61.00	61.00	61.00	60.00	60.00	60.00	60.00	59.00	59.00	59.00	58.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,803	-	-	-	3,004	-	-	-	5,150	-	-	-	4,234	-	-	-	4,628	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	24.5%	-78.93	-104	-130	-122	-121	-129	-118	-132	-14.11	-95.60	-63.16	-125	-24.80	622	-101	-109	-44.89	-71.70	-81.23	-80.19	-67.58
Share Based Compensation	-2.1%	23.00	23.00	24.00	23.00	26.00	24.00	25.00	23.00	23.00	24.00	24.00	21.00	20.00	20.00	20.00	17.00	16.00	15.00	14.00	10.00	9.00
Cashflow From Investing	921.7%	79.00	-9.59	32.00	173	-53.28	-132	77.00	-41.09	-346	104	-115	132	-75.53	-430	12.00	60.00	68.00	75.00	-248	89.00	56.00
Cashflow From Financing	-84.2%	16.00	98.00	-	-	2.00	381	177	1.00	18.00	11.00	15.00	7.00	220	84.00	3.00	310	2.00	4.00	332	2.00	1.00

BPMC Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenue	$ 249,380	$ 204,036	$ 180,080
Cost and operating expenses:
Cost of sales	8,540	17,813	17,934
Research and development	427,720	477,419	601,033
Selling, general and administrative	295,141	237,374	195,293
Collaboration loss sharing	4,256	8,948	7,801
Total cost and operating expenses	735,657	741,554	822,061
Other income (expense):
Interest income (expense), net	(18,793)	(16,767)	2,386
Other income (expense), net	(946)	2,004	(1,489)
Total other income (expense)	(19,739)	(14,763)	897
Loss before income taxes	(506,016)	(552,281)	(641,084)
Income tax expense	968	5,236	3,001
Net loss	(506,984)	(557,517)	(644,085)
Other comprehensive income (loss):
Unrealized gain (loss) on pension benefit obligations	(2,781)	666	4,255
Unrealized gain (loss) on available-for-sale investments	9,759	(7,246)	(3,649)
Currency translation adjustments	(30)	270	475
Comprehensive loss	$ (500,036)	$ (563,827)	$ (643,004)
Net loss per share - basic (in dollars per share)	$ (8.37)	$ (9.35)	$ (11.01)
Net loss per share - diluted (in dollars per share)	$ (8.37)	$ (9.35)	$ (11.01)
Weighted-average number of common shares used in net loss per share - basic (in shares)	60,558	59,642	58,518
Weighted-average number of common shares used in net loss per share - diluted (in shares)	60,558	59,642	58,518
Product revenue, net
Revenues:
Revenue	$ 204,207	$ 110,993	$ 57,687
Product revenue, net \| Nonrelated Party
Revenues:
Revenue	204,207	110,993	57,687
Collaboration and License \| Nonrelated Party
Revenues:
Revenue	$ 45,173	65,543	$ 122,393
License \| Related Party
Revenues:
Revenue		$ 27,500

BPMC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 71,286	$ 119,709
Marketable securities	639,355	825,283
Accounts receivable	42,827	23,525
Unbilled accounts receivable	351	13,413
Inventory	21,223	29,697
Prepaid expenses and other current assets	33,351	35,024
Total current assets	808,393	1,046,651
Marketable securities	56,530	133,480
Property and equipment, net	41,959	33,344
Operating lease right-of-use assets, net	73,691	81,854
Restricted cash	10,238	5,195
Equity investment	27,789	27,789
Other assets	30,650	21,589
Total assets	1,049,250	1,349,902
Current liabilities:
Accounts payable	4,710	2,729
Accrued expenses	127,992	131,123
Current portion of operating lease liabilities	11,933	10,579
Current portion of deferred revenue	812	4,667
Current portion of liabilities related to the sale of future royalties and revenues	39,198	17,285
Current portion of term loan	30,278	16,851
Total current liabilities	214,923	183,234
Operating lease liabilities, net of current portion	81,751	92,789
Deferred revenue, net of current portion	4,792	13,624
Liabilities related to the sale of future royalties and revenues, net of current portion	402,427	413,045
Term loan, net of current portion	208,535	122,232
Other long-term liabilities	6,213	10,301
Total liabilities	918,641	835,225
Commitments and Contingencies (Note 18)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 120,000,000 shares authorized; 61,147,236 and 59,958,919 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	61	60
Additional paid-in capital	2,473,985	2,358,018
Accumulated other comprehensive loss	(3,495)	(10,443)
Accumulated deficit	(2,339,942)	(1,832,958)
Total stockholders' equity	130,609	514,677
Total liabilities and stockholders' equity	$ 1,049,250	$ 1,349,902

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

CEO	Ms. Kathryn Haviland
WEBSITE	blueprintmedicines.com
INDUSTRY	Biotechnology
EMPLOYEES	660

Blueprint Medicines Corp Frequently Asked Questions

What is the ticker symbol for Blueprint Medicines Corp? What does BPMC stand for in stocks?

BPMC is the stock ticker symbol of Blueprint Medicines Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Blueprint Medicines Corp (BPMC)?

As of Fri Apr 19 2024, market cap of Blueprint Medicines Corp is 5.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BPMC stock?

You can check BPMC's fair value in chart for subscribers.

What is the fair value of BPMC stock?

You can check BPMC's fair value in chart for subscribers. The fair value of Blueprint Medicines Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Blueprint Medicines Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BPMC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Blueprint Medicines Corp a good stock to buy?

The fair value guage provides a quick view whether BPMC is over valued or under valued. Whether Blueprint Medicines Corp is cheap or expensive depends on the assumptions which impact Blueprint Medicines Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BPMC.

What is Blueprint Medicines Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, BPMC's PE ratio (Price to Earnings) is -10.49 and Price to Sales (PS) ratio is 21.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BPMC PE ratio will change depending on the future growth rate expectations of investors.